Accessibility Menu
Aclarion logo

Aclarion(NASDAQ) ACON

Market Cap$7.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-100%
5 YearN/A
1 Year-62%
1 Month+7%
$2.76
+12.20%
+0.30Today
After hours$2.78+$0.02 (+0.73%)
Aclarion last closing stock price
MetricPriceDate
Last closeUSD 2.772026-08-17
Aclarion stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+17.37%USD 2.362026-08-10
1 month+7.36%USD 2.582026-07-17
3 month-13.44%USD 3.202026-05-19
Year to date-39.78%USD 4.602025-12-31
1 year-62.15%USD 7.322025-08-15
3 year-100%USD 67,439.522023-08-18
Since inception-100%USD 393,638.112022-04-22

Aclarion Financials at a Glance

Market Cap

$7.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$83.77K

Net Income (TTM)

-$9.20M

EPS (TTM)

-$7.60

P/E Ratio

-0.32

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$2.76

Volume

176,614.594

Open

$2.53

Previous Close

$2.77

Daily Range

$2.47 - $2.78

52-Week Range

$1.95 - $12.03

Estimated Earnings Date

Nov 11, 2026

ACON News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aclarion

Aclarion helps doctors find the source of back pain using software. Its main tools analyze MRI data to guide treatment decisions. Patients and clinicians benefit from more precise, non-invasive diagnosis.

Back Pain, Meet Your Match: Products and Services

  • NOCISCAN: Cloud-based software that analyzes MRI data to identify painful spinal discs (100% of revenue).
  • NOCICALC: Processes raw magnetic resonance spectroscopy (MRS) data to measure pain-related chemicals in spinal discs.
  • NOCIGRAM: Decision support tool that summarizes results for doctors, helping plan treatments for chronic back pain.
  • Service Delivery: Reports delivered to clinicians for use in surgical planning and patient management.
  • Target Users: Physicians treating chronic low back and neck pain, especially those considering surgery.

Growth Spurts and Strategic Moves

  • Expanded MRI scanner compatibility to PHILIPS systems in Q1 2025.
  • Launched the CLARITY Trial in 2025 to support insurance coverage and coding.
  • Formed partnerships with SIEMENS, PHILIPS, ATEC Spine, and RadNet for technology and commercialization.
  • Entered the UK market with insurance reimbursement in 2025, boosting international sales.
  • Developed Nociscan 3.0 and began AI research for future product improvements in 2025.

What Makes Aclarion Stand Out in the Crowd

Aclarion offers a non-invasive way to pinpoint painful spinal discs, using chemical analysis not available with standard MRI. Its technology is supported by exclusive patents and partnerships with major MRI manufacturers. The company’s focus on objective diagnostics addresses a key gap in chronic back pain care.

Five Things You Need to Know

  • Revenue was $75,730 in 2025, up 65.6% from 2024.
  • International sales made up 74% of revenue in 2025.
  • Gross margin improved to 9.0% in 2025 from negative in 2024.
  • Operating loss was $7.05 million in 2025, up 28% from 2024.
  • Cash balance was $12.04 million at December 31, 2025.

Bottom Line

Aclarion has evolved from early-stage development to commercializing a unique diagnostic tool for back pain. The company’s focus on innovation and partnerships supports its efforts to address a challenging medical need.

AI Generated • Apr 16, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

11

CEO

Brent Ness, MBA

Website

www.aclarion.com

Headquarters

Broomfield, CA 80021, US

ACON Financials

Key Financial Metrics (TTM)

Gross Margin

-50.96%

Operating Margin

-11592.14%

Net Income Margin

-10978.48%

Return on Equity

-59.34%

Return on Capital

-54.95%

Return on Assets

-50.98%

Earnings Yield

-3.13%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.88M

Volume

176.61K

Avg. Volume

67.14K

Financials (TTM)

Gross Profit

-$42.69K

Operating Income

-$9.71M

EBITDA

-$8.95M

Operating Cash Flow

-$8.09M

Capital Expenditure

$571.00

Free Cash Flow

-$8.09M

Cash & ST Invst.

$16.29M

Total Debt

$0.00

Aclarion Performance Analysis

Aclarion annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 60,4440.3%
20232023-12-31USD 75,40424.8%
20242024-12-31USD 45,724-39.4%
20252025-12-31USD 75,73065.6%
Aclarion sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-2.0%
Q42025-12-31-2.4%
Q12026-03-3114.4%
Q22026-06-3019.2%
Aclarion annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -177,396.3347.8%
20232023-12-31USD -79,782.69-55.0%
20242024-12-31USD -7,480.22-90.6%
20252025-12-31USD -13.61-99.8%
Aclarion sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-6.6%
Q42025-12-3124.6%
Q12026-03-3139.4%
Q22026-06-3016.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$25.21K

+30.5%

Gross Profit

$8.30K

+61.4%

Gross Margin

32.91%

N/A

Market Cap

$7.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$644.60K

N/A

Employees

11

N/A

Net Income

-$2.75M

-71.6%

EBITDA

-$2.69M

-73.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$16.29M

+26.6%

Total Debt

$0.00

N/A

Accounts Receivable

$28.17K

+34.7%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-50.98%

N/A

Return on Invested Capital

-57.11%

N/A

Free Cash Flow

-$2.61M

-39.7%

Operating Cash Flow

-$2.66M

-42.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENSCEnsysce Biosciences, Inc.
$0.38-5.83%
SNGXSoligenix, Inc.
$0.38-4.70%
BFRGBullfrog AI Holdings, Inc. Common Stock
$0.56-2.24%
SILOSilo Pharma, Inc.
$3.07-4.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.61-0.02%
SPCXSpace Exploration Technologies
$146.23+0.04%
IPSTIp Strategy
$7.39+2.36%
NVDANvidia
$225.01-0.00%

Questions About ACON

What is the current price of Aclarion?

Aclarion is trading at $2.77 per share.

What is the 52-week range for Aclarion?

Over the past 52 weeks, Aclarion has traded between $1.95 and $12.03.

How much debt does Aclarion have?

As of the most recent reporting period, Aclarion reported total debt of $0.00.

How much cash does Aclarion have on hand?

Aclarion reported $16.31M in cash and cash equivalents in its most recent financial results.

What is Aclarion’s dividend yield?

Aclarion does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services